{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-003600","form_type":"8-K","ticker":"PTN","cik":"0000911216","company_name":"PALATIN TECHNOLOGIES INC","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.768549+00:00","generated_at":"2026-05-24T02:46:53.211150+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Palatin reports positive Phase 2 topline results for UC drug PL8177 and obesity combo study","bullets":["UC Phase 2: Clinical remission 33% PL8177 vs 0% placebo; clinical response 78% vs 33% (p<0.005) after 8 weeks.","Obesity Phase 2: Co-admin bremelanotide + tirzepatide met primary endpoint with 4.4% weight loss vs 1.6% placebo (p<0.0001).","Obesity: 40% of co-admin group achieved 5% weight loss (p<0.05); low-dose bremelanotide stopped weight regain post-tirzepatide.","Next-gen MC4R long-acting peptides and oral small molecules; IND applications planned for 4Q25, clinical data 1H26.","Licensing discussions for UC program advancing with multiple big pharma companies."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-003600","json":"https://secwatch.observer/filing/0001654954-25-003600.json","markdown":"https://secwatch.observer/filing/0001654954-25-003600.md","text":"https://secwatch.observer/filing/0001654954-25-003600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/911216/000165495425003600/0001654954-25-003600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/911216/000165495425003600/ptn_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:46:53.211150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}